Enterprise Value
56.85M
Cash
91.28M
Avg Qtr Burn
-10.55M
Short % of Float
7.78%
Insider Ownership
2.18%
Institutional Own.
22.47%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iomab-B (CD45) (apamistamab-I-131) Details Hematopoietic cell transplantation , Acute myeloid leukemia | BLA Submission | |
Iomab-ACT (CAR-T – CD45) Details Lymphoma, Diffuse large B cell lymphoma | Phase 1/2 Data readout | |
Actimab-A + venetoclax Details Relapsed/refractory acute myeloid leukemia | Phase 1/2 Data readout | |
Actimab-A + CLAG-M Details Relapsed/refractory acute myeloid leukemia | Phase 1 Update | |
Iomab-ACT (GeneTx – CD45) Details Lymphoma, Acute radiation syndrome | Failed Discontinued | |
Actimab-A + venetoclax Details Myelodysplastic syndrome | Failed Discontinued |